Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.66 Analyst target: $8.29 Upside: 399.40%
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
See the full interactive analysis & chart →Informational only — not investment advice.